Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing

Sophie J. Bakri, Melissa R. Snyder, Jose S Pulido, Colin A. McCannel, William T. Weiss, Ravinder Jit Singh

Research output: Contribution to journalArticle

87 Scopus citations


PURPOSE: To determine the change in anti-vascular endothelial growth factor (VEGF) activity of bevacizumab (Avastin, Genentech, Inc., San Francisco, CA) after refrigeration or freezing. METHODS: Samples of bevacizumab were drawn up from new vials into plastic tuberculin syringes and refrigerated at 4°C for 1 week, 3 weeks, 1 month, 3 months, and 6 months. The vials and syringes were stored at 4°C, and the syringes were capped with a needle. One syringe was frozen at -10°C. The bevacizumab concentration was measured, via its binding to VEGF-165. RESULTS: The percentage of degradation of bevacizumab in the previously pierced vials stored at 4°C compared with that in the unpierced vial was 9.6% at 3 months and 12.7% at 6 months. The bevacizumab drawn into the syringe and stored at 4°C was degraded by 1.6% at 1 week, 0% at 3 weeks, 8.8% at 3 months, and 15.9% at 6 months. The bevacizumab frozen in a syringe at -10°C was degraded by 12.0% at 6 months. CONCLUSION: The anti-VEGF activity of bevacizumab may degrade minimally over time, with storage.

Original languageEnglish (US)
Pages (from-to)519-522
Number of pages4
Issue number5
StatePublished - May 2006



  • Activity
  • Assay
  • Bevacizumab (Avastin)
  • Biologic
  • Choroidal neovascularization
  • Concentration
  • Frozen
  • Immunoassay
  • Refrigerated
  • Stability
  • Syringe
  • Vascular endothelial growth factor
  • Vial

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this